Details of the Drug

General Information of Drug (ID: DMDK7T9)

Drug Name
SBC-102
Synonyms Sebelipase alfa; Enzyme replacement therapy (protein recombinant, lysosomal acid lipase deficiency), Synageva BioPharma
Indication
Disease Entry ICD 11 Status REF
Enzyme deficiency 5C51-5C57 Approved [1]
Sequence
>Sebelipase alfa protein sequence
SGGKLTAVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPV
VFLQHGLLADSSNWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWA
FSYDEMAKYDLPASINFILNKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALG
PVASVAFCTSPMAKLGRLPDHLIKDLFGDKEFLPQSAFLKWLGTHVCTHVILKELCGNLC
FLLCGFNERNLNMSRVDVYTTHSPAGTSVQNMLHWSQAVKFQKFQAFDWGSSAKNYFHYN
QSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNILLTQITNLVFHESIPEWEHLDFIWGL
DAPWRLYNKIINLMRKYQ
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 942 mcgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 490 mcg/L [2]
Clearance
The clearance of drug is 31.1-38.2 L/h [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 5.4 - 6.6 minutes [2]
Metabolism
The drug is metabolized via the catabolism to smaller peptides and amino acids []
Vd
The volume of distribution (Vd) of drug is 3.6 L [2]
Cross-matching ID
TTD ID
D0CH4A

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lysosomal acid lipase (LIPA) TTS8T1M LICH_HUMAN Modulator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01757184) A Multicenter Study of SBC-102 (Sebelipase Alfa) in Patients With Lysosomal Acid Lipase Deficiency/ ARISE (Acid Lipase Replacement Investigating Safety and Efficacy).U.S. National Institutes of Health.
2 FDA Approved Drug Products: Kanuma (sebelipase alfa) for intravenous injection
3 A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. N Engl J Med. 2015 Sep 10;373(11):1010-20.